Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure

Canadian Journal of Cardiology

Volumn 32, Issue 5, 2016, Pages 603-606

  Siddiqui, Mohammed ^a   Dudenbostel, Tanja ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; THIAZIDE DIURETIC AGENT; DIURETIC AGENT;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DRUG TREATMENT FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PREVALENCE; RACE DIFFERENCE; RESISTANT HYPERTENSION; SEX DIFFERENCE; SLEEP DISORDERED BREATHING; TREATMENT OUTCOME; TREATMENT RESPONSE; ADRENERGIC SYSTEM; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT FAILURE; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG RESISTANCE; HUMANS; HYPERTENSION; PREVALENCE; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT FAILURE; UNITED STATES;

EID: 84951087365     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.06.033     Document Type: Article

References (14)

1. Setaro J.F., Black H.R. Refractory hypertension. N Engl J Med 1992, 327:543-547.
2. Redon J., Campos C., Narciso M.L., et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998, 31:712-718.
3. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
4. Acelajado M.C., Pisoni R., Dudenbostel T., et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens 2012, 14:7-12.
5. Calhoun D.A., Booth J.N., Oparil S., et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014, 63:451-458.
6. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
7. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
8. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
9. Khosla N., Chua D.Y., Elliott W.J., Bakris G.L. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?. J Clin Hypertens 2005, 7:354-356.
10. Sim J.J., Bhandari S.K., Shi J., et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013, 88:1099-1107.
11. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-404.
12. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
13. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
14. Pimenta E., Gaddam K.K., Oparil S., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.